PFM Health Sciences’s Procept Biorobotics PRCT Stock Holding History

PFM Health Sciences’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-295,544	Closed	-$10.4M	–	82
2023 Q2	$10.4M	Sell	295,544 -24,238	-8%	-$801K	0.41%	59
2023 Q1	$9.08M	Sell	319,782 -197,744	-38%	-$6.98M	0.4%	59
2022 Q4	$21.5M	Hold	517,526	–	–	0.77%	50
2022 Q3	$21.5M	Buy	517,526 +160,034	+45%	+$6.38M	0.78%	52
2022 Q2	$11.7M	Buy	+357,492	New	+$13M	0.45%	56
2022 Q1	–	Sell	-65,000	Closed	-$1.63M	–	76
2021 Q4	$1.63M	Hold	65,000	–	–	0.06%	70
2021 Q3	$2.48M	Buy	+65,000	New	+$2.49M	0.07%	82

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFM Health Sciences's PRCT Position: Q3 2023 in Review

PFM Health Sciences sold out of Procept Biorobotics (PRCT) in Q3 2023, closing a stake of 295,544 shares — an estimated $10.4M sold.

PFM Health Sciences first reported a position in PRCT in Q3 2021 and held it in 7 quarters. The position peaked at $21.5M in Q4 2022. 127 funds tracked by Wall St. Rank hold PRCT as of Q3 2023.

PFM Health Sciences reported no remaining Procept Biorobotics position as of Q3 2023 after selling out during the quarter.
PFM Health Sciences sold 295,544 Procept Biorobotics shares in Q3 2023, an estimated $10.4M.
PFM Health Sciences first reported a position in Procept Biorobotics in Q3 2021 and held it in 7 quarters.
PFM Health Sciences's Procept Biorobotics position peaked at $21.5M in Q4 2022.
127 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2023.

Based on PFM Health Sciences's 13F filing for Q3 2023, filed 14 Nov 2023.